Reata to seek approval for Friedreich’s ataxia drug on positive Phase II results
Shares of Texas-based Reata rose 60 percent Tuesday following the announcement of results from its registration-directed Phase II study of omaveloxolone. The company reacquired rights to that and other drugs from AbbVie last week. FA has no approved treatments.